obesity treatment with bariatric surgery vs glp-1 receptor agonists Outperforms GLP-1s in Weight Loss Metabolic and bariatric surgery versus

The GIP receptor is a seven-transmembrane G protein-coupled receptor strongly expressed on islet cells, which has been found in many tissues including the pancreas, adipose tissue, heart, gastrointestinal tract, adrenal cortex, and various neurons in the brain [99]

These results are compelling

Subsequently, in August 2025, semaglutide, a representative drug of GLP-1RAs, also obtained FDA approval, targeting the same indications as Resmetirom (8)

Deviations from intended interventions

Early studies indicate GLP-1s should be researched further as possible treatments for alcohol use and substance use disorders, nicotine addiction, and compulsive behaviors